Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Revance Therapeutics (RVNC) Stock Price & Analysis
554 Followers
RVNC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.00 - $33.71
Previous Close$3.31
Volume1.92M
Average Volume (3M)2.03M
Market Cap
$345.72M
Enterprise Value$570.24M
Total Cash (Recent Filing)$253.91M
Total Debt (Recent Filing)$478.43M
Price to Earnings (P/E)-0.9
Beta1.40
Next Earnings
Aug 06, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.63
Shares Outstanding104,448,502
10 Day Avg. Volume2,516,741
30 Day Avg. Volume2,030,433
Standard Deviation0.24
R-Squared0.07
Alpha-0.00642
Financial Highlights & Ratios
Price to Book (P/B)-2.25
Price to Sales (P/S)1.48
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$13.40Price Target Upside325.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Revance Therapeutics News
PremiumCompany Announcements
Revance Therapeutics Launches DAXXIFY® for Cervical Dystonia
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe company reiterated its 2024 guidance, indicating confidence in its financial projections.
Product StrategyImproved launch traction for Daxxify due to its competitive pricing strategy, pointing to Daxxify market share gains.
Stock ValuationAnalyst maintains a Buy rating based on the depressed valuation that may not fully reflect the company's product portfolio potential.
Bears Say
Financial PerformanceEPS loss was wider than consensus, and the top line missed the below-consensus forecast.
Market ConfidenceInvestor confidence in the company was shaken when the company abruptly shifted its pricing strategy for Daxxify and performance fell short of consensus.
Product PerformanceDaxxify's revenue fell short of expectations with a quarter-over-quarter decrease, raising concerns about meeting the annual guidance.
---
Ownership Overview
12.84% Insiders
33.94% Mutual Funds
48.58% Other Institutional Investors
4.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $3.00 and its highest was $33.71 in the past 12 months.
What is Revance Therapeutics’s market cap?
Currently, no data Available
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 81 days.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on May 09, 2024. The company reported -$0.443 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.019.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -$0.36.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 104,448,500 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.443 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -22.611%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Moore Capital Management LP. It holds Revance Therapeutics’s shares valued at 738K.
---
Revance Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.40 (325.40% Upside)
$13.40 (325.40% Upside)
Blogger Sentiment
Neutral
RVNC Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 10.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.24%
Trailing 12-Months
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
---
RVNC Earnings Call
Q1 2024
0:00 / 0:00
---
RVNC Stock 12 Month Forecast
Average Price Target
$13.40
▲(325.40% Upside)
Technical Analysis
Best Analysts Covering RVNC
1 Year
1 Year Success Rate
15/36 ratings generated profit
1 Year Average Return
-6.63%
reiterated a buy rating 7 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -6.63% per trade.
---